These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28730751)

  • 1. Tuberculosis and biologics in rheumatology: A special situation.
    Handa R; Upadhyaya S; Kapoor S; Jois R; Pandey BD; Bhatnagar AK; Khanna A; Goyal V; Kumar K
    Int J Rheum Dis; 2017 Oct; 20(10):1313-1325. PubMed ID: 28730751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
    Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
    Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients.
    Wang PH; Lin CH; Chang TH; Wu CS
    BMC Pulm Med; 2020 Aug; 20(1):232. PubMed ID: 32867745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
    Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
    Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.
    Scrivo R; Armignacco O
    Int J Rheum Dis; 2014 Sep; 17(7):716-24. PubMed ID: 24725559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
    Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
    Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
    Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
    Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of interferon-gamma release assay (T-SPOT.TB(™) ) for diagnosis of tuberculosis infection in rheumatic disease patients.
    Jiang B; Ding H; Zhou L; Chen X; Chen S; Bao C
    Int J Rheum Dis; 2016 Jan; 19(1):38-42. PubMed ID: 26820838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
    So H; Yuen CS; Yip RM
    Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
    Goletti D; Petrone L; Ippolito G; Niccoli L; Nannini C; Cantini F
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):501-512. PubMed ID: 29848120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.
    Kurti Z; Lovasz BD; Gecse KB; Balint A; Farkas K; Morocza-Szabo A; Gyurcsanyi A; Kristof K; Vegh Z; Gonczi L; Kiss LS; Golovics PA; Lakatos L; Molnar T; Lakatos PL
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):467-72. PubMed ID: 26697573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence of active tuberculosis following resumption of anti-TNF-α therapy in a patient with Crohn's disease.
    Masiá M; Martínez M; García-Sepulcre MF; Sáez J; Gutiérrez F
    Int J Tuberc Lung Dis; 2014 Feb; 18(2):249-50. PubMed ID: 24429322
    [No Abstract]   [Full Text] [Related]  

  • 20. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.